As with previous HPV vaccines, the 9-valent vaccine is covered by the large majority of insurance plans, said Dr. ... It's well-intentioned but confusing as it sets the HPV vaccine apart from all other universally recommended vaccines,” Dr.
The 10 vaccines were hepatitis A; hepatitis B; human papillomavirus vaccine (HPV); combined measles, mumps, and rubella (MMR); meningococcal conjugate vaccine (MCV4); pneumococcal polysaccharide (PPSV23); tetanus diphtheria (Td); combined tetanus,
1) Why does CDC utilize outpatient, sick controls in their estimates of vaccine efficacy? ... It appears this case-control method is standard in the influenza vaccine literature.
QD: News Every Day--H1N1 'emergency' and vaccine shortage. ACP Internist's daily digest of news and events continues with H1N1 updates, and physicians speaking out about health care reform. ... H1N1 influenza. The weekend's health news had one theme:
This regulatory update covers changed labeling for heparin and approval of a flu vaccine produced using cultured animal cells. ... In a trial, the vaccine was 83.8% effective in preventing influenza compared to placebo.
This has been a wrenching issue for many families who are convinced that measles (MMR vaccine) or other vaccines caused their children to develop this serious illness. ... While every vaccine, including measles, has potential side-effects, these are rare
A trivalent vaccine (Fluad) for the prevention of seasonal influenza in people ages 65 years and older. ... In a trial of 7,082 older participants, the new vaccine and an existing one (Agriflu) induced comparable antibody levels.
annually, causing hundreds of deaths. In 1963 the measles vaccine was introduced, leading to an immediate decrease of measles cases in this country. ... These numbers have much to teach about how vaccines work and how they don't work.
Was this year's flu vaccine good enough? Let me tell you about two patients. ... This is on par with previous data on flu vaccines. Some studies have shown much less benefit in older adults.
A vaccine (Trumenba) to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B in patients 10 through 25 years. ... Previously, FDA-approved meningococcal vaccines only covered serogroups A, C, Y, and W.